SCHEMBL1875466

SCHEMBL1875466

CC(C)(C)OC(=O)N1CCC(N2Cc3cccc(C(=O)O)c3C2=O)CC1

nearest known ligand 0.76

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.59
PARP2 Q9UGN5 3/20 0.56
ALDH1A1 P00352 5/20 0.55
MAPT P10636 4/20 0.55
NPSR1 Q6W5P4 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
GAA P10253 1/20 0.54
USP2 O75604 1/20 0.51
LMNA P02545 1/20 0.51
POLB P06746 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1868956 0.91 PARP1 (0.73) PARP1PARP2POLB
SCHEMBL29802845 0.91 PARP1 (0.73) PARP1PARP2POLB
SCHEMBL835492 0.84 PARP1 (0.50) PARP1PARP2ALDH1A1MAPTNPSR1
SCHEMBL6128734 0.82 PARP1 (0.53) PARP1PARP2ALDH1A1
SCHEMBL3098616 0.81 TP53 (0.51) L3MBTL1
SCHEMBL1907164 0.80 PARP1 (0.53) PARP1KMT2AMEN1
SCHEMBL834075 0.78 USP30 (0.47) PARP1PARP2ALDH1A1MAPTNPSR1
SCHEMBL29802944 0.78 GPR119 (0.47) PARP1NPSR1KMT2AMEN1USP2
SCHEMBL1861959 0.78 PARP1 (0.79) PARP1PARP2ALDH1A1MAPTKMT2A
SCHEMBL834012 0.78 PARP1 (0.78) PARP1PARP2ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773064-B2 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-10-03 US disclosed
US-20220363636-A1 4-CARBOXAMIDO-ISOINDOLINONE DERIVATIVES AS SELECTIVE PARP-1 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2022-11-17 US disclosed
US-11420940-B2 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2022-08-23 US disclosed
EP-2454236-B1 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2019-09-04 EP disclosed
US-8877944-B2 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-11-04 US disclosed
US-20120245142-A1 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-09-27 US disclosed
EP-2454236-A1 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-05-23 EP disclosed
WO-2011006794-A9 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773064-B2 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors PARP1, PARP2, PARP12 PARP1 1/4885PARP2 2/4885ALDH1A1 539/4885
US-11420940-B2 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors PARP1, PARP2, PARP11 PARP1 1/4885PARP2 2/4885ALDH1A1 235/4885
US-20220363636-A1 4-CARBOXAMIDO-ISOINDOLINONE DERIVATIVES AS SELECTIVE PARP-1 INHIBITORS PARP1, PARP2, PARP12 PARP1 1/4885PARP2 2/4885ALDH1A1 560/4885
US-20120245142-A1 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS PARP1, PARP2, PARP3 PARP1 1/4885PARP2 2/4885ALDH1A1 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.